Jikang Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jikang Wu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Haibo Qiu
Analytical Chemistry, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA
4 shared publications - Ning Li
Analytical Chemistry, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA
3 shared publications Yu Zhang
Analytical Chemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591-6707, United States
3 shared publications- Aishwarya Saraswat
Drug Product Development & Technology, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA
1 shared publication - Alireza Nomani
Drug Product Development & Technology, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA
1 shared publication - Amardeep Singh Bhalla
Drug Product Development & Technology, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 18 February 2026
- Published by MDPI AG in Nanomaterials
- Vol. 16 (4) , 268
Identifying Key Factors Affecting mRNA-Lipid Nanoparticles Drug Product Formulation Stability
Background: The long-term stability of mRNA-lipid nanoparticles (LNPs), essential for mRNA vaccines and gene therapies, relies on managing physicochemical properties to preserve their integrity and effectiveness through optimized formulation components. This study systematically evaluated LNP formulations with varied compositions, e.g., Dlin-MC3-DMA and ALC-0315 as ionizable lipids, and DMG-PEG2k or ALC-0159 as polyethylene glycol (PEG)-lipids, stored at −80 °C, −20 °C, 5 °C, and 25 °C in Tris buffer (pH 7.4) for 12 months. Methods: Sixteen quality attributes were analyzed, including particle size, mRNA encapsulation, lipid oxidation, and transfection efficiency over different formulations and storage temperatures to mechanistically evaluate the long-term stabilities. Results: Formulations stored at −80 °C and −20 °C retained acceptable stability, while storage at 5 °C caused aggregation, reduced in vivo expression, and mRNA degradation. Storage at 25 °C led to complete loss of transfection within six months. Mechanistic studies identified oxidative and hydrolytic lipid degradation (e.g., DSPC) in ALC-0315 formulations and MC3 N-oxidation with subvisible particulates in MC3-containing LNPs as primary failure modes. Increasing Tris buffer concentration accelerated 5′-cap hydrolysis, emphasizing the importance of a low-ionic-strength buffer for LNP formulations. Conclusions: Findings re-emphasize the necessity of deep-cold storage (≤−20 °C) and optimized formulation components to preserve mRNA–LNP integrity, offering insights for designing next-generation LNPs with improved shelf-life.
- 18 February 2026
- Published by MDPI AG in Nanomaterials
- Vol. 16 (4) , 268
Top Cited PapersOpen AccessIdentifying Key Factors Affecting mRNA-Lipid Nanoparticles Drug Product Formulation Stability
Background: The long-term stability of mRNA-lipid nanoparticles (LNPs), essential for mRNA vaccines and gene therapies, relies on managing physicochemical properties to preserve their integrity and effectiveness through optimized formulation components. This study systematically evaluated LNP formulations with varied compositions, e.g., Dlin-MC3-DMA and ALC-0315 as ionizable lipids, and DMG-PEG2k or ALC-0159 as polyethylene glycol (PEG)-lipids, stored at −80 °C, −20 °C, 5 °C, and 25 °C in Tris buffer (pH 7.4) for 12 months. Methods: Sixteen quality attributes were analyzed, including particle size, mRNA encapsulation, lipid oxidation, and transfection efficiency over different formulations and storage temperatures to mechanistically evaluate the long-term stabilities. Results: Formulations stored at −80 °C and −20 °C retained acceptable stability, while storage at 5 °C caused aggregation, reduced in vivo expression, and mRNA degradation. Storage at 25 °C led to complete loss of transfection within six months. Mechanistic studies identified oxidative and hydrolytic lipid degradation (e.g., DSPC) in ALC-0315 formulations and MC3 N-oxidation with subvisible particulates in MC3-containing LNPs as primary failure modes. Increasing Tris buffer concentration accelerated 5′-cap hydrolysis, emphasizing the importance of a low-ionic-strength buffer for LNP formulations. Conclusions: Findings re-emphasize the necessity of deep-cold storage (≤−20 °C) and optimized formulation components to preserve mRNA–LNP integrity, offering insights for designing next-generation LNPs with improved shelf-life.
- Open Access
- 17 January 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1390, 345113
High-throughput copper speciation with SEC-UV-ICPMS: Insights from Wilson's disease mouse models
- 17 January 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1390, 345113
Open AccessHigh-throughput copper speciation with SEC-UV-ICPMS: Insights from Wilson's disease mouse models
- Open Access
- 15 March 2025
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1351, 343944
Characterization of lipid nanoparticles using macro mass photometry: Insights into size and mass
- 15 March 2025
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1351, 343944
Open AccessCharacterization of lipid nanoparticles using macro mass photometry: Insights into size and mass
- Open Access
- 30 December 2024
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1338, 343595
Investigating residual trace metals in recombinant monoclonal antibodies to facilitate drug development with LC-UV-ICPMS-HRMS
- 30 December 2024
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1338, 343595
Open AccessInvestigating residual trace metals in recombinant monoclonal antibodies to facilitate drug development with LC-UV-ICPMS-HRMS